...
首页> 外文期刊>Biomaterials >Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles
【24h】

Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles

机译:通过多糖纳米颗粒递送的靶向生存素的siRNA诱导的小鼠抗肿瘤作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Recently, survivin has been attracting great attention because it plays an important role in inhibiting the apoptosis process of tumor cells. Down-regulating the expression of survivin gene by small interfering RNA (siRNA) offers a promising method for anti-tumor therapy. However, lack of appropriate siRNA delivery vector has significantly hindered the successful application of survivin-targeted siRNA in anti-tumor therapy. The purpose of this study was to use polysaccharide vector TAT-g-CS we synthesized to deliver functional siRNA and evaluate its invivo anti-tumor activity. TAT-g-CS vector was firstly synthesized and well structurally characterized. MTT assay showed that TAT-g-CS vector exhibited good biocompatibility. TAT-g-CS complexed with siRNA offering nanoparticles with an average particle size of 212.2nm and a polydispersity index of 0.121, and the zeta potential of the nanoparticles was+18.58mV. Results from reporter gene assay suggested that luciferase-targeted siRNA when delivered by TAT-g-CS could down-regulate the expression of luciferase gene with 75.3% reduction. Most importantly, we use siRNASur targeting survivin gene to assess the invitro and invivo delivery capacity of TAT-g-CS and its anti-tumor effects. Our results demonstrated that TAT-g-CS/siRNASur nanoparticles not only strongly inhibited the invitro proliferation of 4T1-Luc tumor cells via inducing cell apoptosis, but also effectively inhibited the invivo growth and metastasis of malignant breast tumor, which suggested that TAT-g-CS/siRNA nanoparticle was a highly efficient non-viral system for siRNA delivery, especially for anti-tumor therapy based on siRNA therapeutics.
机译:近年来,由于存活蛋白在抑制肿瘤细胞的凋亡过程中起着重要的作用,因此引起了极大的关注。通过小干扰RNA(siRNA)下调survivin基因的表达为抗肿瘤治疗提供了一种有希望的方法。但是,缺乏合适的siRNA传递载体已严重阻碍了survivin靶向siRNA在抗肿瘤治疗中的成功应用。这项研究的目的是使用我们合成的多糖载体TAT-g-CS来递送功能性siRNA并评估其体内抗肿瘤活性。 TAT-g-CS载体是首先合成的,并在结构上得到了很好的表征。 MTT分析表明TAT-g-CS载体表现出良好的生物相容性。 TAT-g-CS与siRNA络合,可提供平均粒径为212.2nm,多分散指数为0.121的纳米粒子,且纳米粒子的zeta电位为+ 18.58mV。报告基因测定的结果表明,通过TAT-g-CS递送的荧光素酶靶向的siRNA可以下调荧光素酶基因的表达,降低75.3%。最重要的是,我们使用靶向survivin基因的siRNASur来评估TAT-g-CS的体内和体外传递能力及其抗肿瘤作用。我们的结果表明,TAT-g-CS / siRNASur纳米颗粒不仅通过诱导细胞凋亡强烈抑制4T1-Luc肿瘤细胞的体外增殖,而且还有效抑制了恶性乳腺肿瘤的体内生长和转移,这表明TAT-g -CS / siRNA纳米颗粒是用于siRNA输送的高效非病毒系统,尤其是基于siRNA治疗剂的抗肿瘤治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号